Services and products for preclinical and clinical research
Stem cell and drug discovery scientists around the world use our solutions to translate their research into therapies.
Service Areas
Featured Products
%20vial.jpg)
Whatʼs New
New Products for MSC Research
REPROCELL offers a variety of ready-to-ship products to support research with MSCs (also known as Mesenchymal Stem Cells, Mesenchymal Stromal Cells, or Medicinal Signaling Cells). These products include primary MSCs, iPSC-derived cell lines, media, and other culture reagents. Our cell lines are useful for differentiation and exosome production, enabling the development of diverse disease models for advanced research.
Clinical MSC Production Service
Mesenchymal Stem Cells (MSCs)—also called Mesenchymal Stromal Cells or Medicinal Signaling Cells—are involved in a variety of cell therapy and drug discovery programs. REPROCELL can help you drive your next clinical MSC project to success and ensure compliance with regulatory agencies.
Human Tissue Pharmacology
Human fresh tissue testing bridges the gap between animal studies and clinical trials. We specialize in proof of concept studies in patient-derived living tissues, increasing your clinical success rates and adding commercial value to your preclinical drug assets.
Alvetex® Bioengineered 3D Tissue Services
Complementing our fresh tissue assays by accurately recreating human biology in bioengineered tissues.
Stem Cell Services for Cell Therapy Manufacturing
GMP iPSC and MSC Master Cell Banks and cells for your cell therapy project. Compliant with regulatory standards of the FDA, EMA, and PDMA.
StemEdit™ Clinical Gene Editing Service
Achieve the genotype you need using CRISPR-SNIPER, before moving on to expensive cell bank manufacturing processes.
Global Oligonucleotide Synthesis Services
Exceptional quality oligos delivered worldwide. Custom synthesis, purification, and modification – all based on your requirements.
Blog
Able Biott Single-use Bioreactors Enhance the Development of Disease Models and Cell Therapy
Discover how Able Biott single-use bioreactors enhance disease modeling and cell therapy development through scalable, efficient iPSC culture solutions.
03 July 2025
Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025
New Therapeutic Targets: The Role of IL17-Related Genes in Precision Medicine
Discover how IL-17 related genes could revolutionize psoriasis treatment, offering new therapeutic targets and paving the way for precision medicine advancements.
09 June 2025
Balancing Efficacy and Cognitive Health In Bladder Assays
New approaches in OAB treatment focus on balancing efficacy and cognitive health, using alternatives to anticholinergics and personalized medicine to improve patient outcomes.
23 May 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Come meet us on 4 September 2025 / Maryland, USA. Venue: Bethesda North Marriott Hotel & Conference Center
Come meet us on 6-8 October (in person) & 9-10 October (virtual) at Phoenix, AZ, USA. Venue: Arizona Biltmore
Corporate News
Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration
Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.
02 July 2025
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
05 May 2025
REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc., reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy "Stemchymal®". REPROCELL holds the exclusive commercialization license agreement for Stemchymal in Japan for the treatment of Spinocerebellar Ataxia (SCA).
25 April 2025